VivoSeq
Dermatology

Oral Lichen Planus

56

Pipeline Programs↗

15

Active Trials↗

16

Companies Involved↗

Oral Lichen Planus is a moderately active landscape with 56 programs across 16 companies. The most active players are Veloxis Pharmaceuticals, Bayer, LEO Pharma. 16 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

19/100

Mech. Concentration

32/100

Completion Rate

91/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Veloxis Pharmaceuticals

1 program

Phase 1Bayer logo

Bayer

2 programs

Phase 2LEO Pharma logo

LEO Pharma

1 program

Phase 2P

Primus Pharmaceuticals

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical8

Efalizumab

Roche

Curcumin in Nanogels

Chulalongkorn University

Zinc Supplement

Hamilton Health Sciences Corporation

Nystatin

Good Molecules, LLC

Fluocinolone

National Eye Institute (NEI)

Phase 110

Quercetin

Mayo Clinic

Tacrolimus

Veloxis Pharmaceuticals

Triamcinolone

Bassett Healthcare

Chamomile

Hams Hamed Abdelrahman

Triamcinolone in Orabase

Mona Taha Mohammed MD

Phase 215

Baricitinib

Eli Lilly

Platelet Rich Plasma

Zagazig University

Hydroxychloroquine

Alnylam Pharmaceuticals

Photodynamic Therapy

Roswell Park Cancer Institute

Clobetasol Propionate

Bayer

Phase 37

Curcumin

Merck & Co.

Pimecrolimus

Bausch Health Americas, Inc.

Dexamethasone

Aspen Global Incorporated

Minocycline

Triax

Ibuprofen

Kenvue Brands

Approved16

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Selenium

SWOG Cancer Research Network

Betamethasone

Schering-Plough

Prednisone

Roxane Laboratories

Sirolimus

Prism Pharmaceuticals

Analysis

Modality Breakdown

96%

Small molecule

76 of 79 classified programs — the dominant modality here.

4%ALL OTHERSProtein / enzyme23%Monoclonal antibody11%

Small molecule leads; the ring shows all 79 classified programs, each share of the total. Modality classified for 100% of 82 pipeline programs.

Analysis

Trial Status

77

clinical trials

Completed43 · 56%
Unknown status15 · 19%
Recruiting8 · 10%
Active, not recruiting4 · 5%
Terminated2 · 3%
Not yet recruiting2 · 3%
Other3 · 4%

Clinical Trials

Trial Activity

77 trials

The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus
Recruiting·—·N/A·NCT06932848·30 enrolled
Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus
Recruiting·UUniversity of Palermo·Phase 2·NCT07100613·45 enrolled
Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus
Recruiting·—·Phase 4·NCT07131813·60 enrolled
Photobiomodulation, Er:YAG Laser, and Clobetasol in the Treatment of Oral Lichen Planus.
Recruiting·MMedical University of Silesia·N/A·NCT07278999·60 enrolled
Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy
Recruiting·PPeking University Third Hospital·N/A·NCT05973097·156 enrolled
Treatment Outcomes and Patient Satisfaction of Oral Lichen Planus Treatment
Recruiting·—·Phase 2/3·NCT06988527·56 enrolled
Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus
Recruiting·—·Phase 2·NCT06981767·42 enrolled
Evaluation of the Efficacy of 0.08% Tacrolimus Nanoencapsulated Aqueous Solution Spray Vs. 0.1% Free Tacrolimus Commercial Ointment in the Treatment of Oral Lichen Planus
Recruiting·HHospital de Clinicas de Porto Alegre·Phase 1/2·NCT06591884·46 enrolled
Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study
Active, not recruiting·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT06158113·10 enrolled
Topical Sulfasalazine and Oral Lichen Planus
Active, not recruiting·—·Phase 3·NCT06060301·46 enrolled
Melatonin Epigenetic Potential in Preventing Malignant Transformation of Oral Lichen Planus
Active, not recruiting·—·N/A·NCT06533033·50 enrolled
Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.
Active, not recruiting·MMalmö University·Phase 2/3·NCT04364555·90 enrolled
Efficacy of Coconut Gel Compared to Corticosteroid Gel in the Management of Oral Lichen Planus
Not yet recruiting·—·Phase 4·NCT07100145·30 enrolled
Periodontal Initial Treatment Combined With Glucocorticoid Therapy for Erosive Oral Lichen Planus
Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·N/A·NCT06498180·29 enrolled
Thyme Honey for Management of Oral Lichen Planus
Enrolling by invitation·—·Phase 1/2·NCT06810752·30 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)